A Phase 1 interventional study of Botulinum toxin type A injection and Botulinum Toxin Type A Injection [Botox] in Overactive Bladder, sponsored by Hugel. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by Hugel · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 33rd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1, and was the 37th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:
Mackay Medical College · Sites in Taiwan
Ages 30–100 · Women only
University of South Florida · Sites in United States
Ages 18+ · Women only
Walter Reed National Military Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 19 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 18 · Phase 4 10
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 84 across the 44 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 44 have an industry lead sponsor. The 10 most frequent:
Hugel is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Hugel has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial to Compare the Safety and Efficacy of Botulax® versus Botox® in Patient with Overactive Bladder
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with idiopathic overactive bladder who meets the following conditions:
Exclusion Criteria:
Subjects who are eligible for any of the following conditions may not participate in this study:
Subjects with the following comorbidities:
Subjects with Urinary Tract Infections*
* Culture showing ≥10\^5 colony-forming units (CFU)/mL and leukocytes ≥5 high power field (HPF)
Uncontrolled diabetes patients who meet one or more of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Botulinum toxin type A injection
Drug: Botulinum Toxin Type A Injection [Botox]
Experimental
Also known as: Botulax®
Active Comparator
Also known as: Botox®
Adverse event incidence rates
To assess severity and frequency of reported TEAE (treatment-emergent adverse event), ADR (adverse drug reaction), and SAE (serious adverse event) after investigational product injection
Time frame: 12 weeks (during the clinical trial)
Urinary incontinence rate
The change in the average number of Urinary incontinence per day at 2, 6 and 12 weeks from baseline
Time frame: Baseline to Week 2, Week 6, Week 12
Voiding frequency rate
The change in the average number of voiding frequency per day at 2, 6 and 12 weeks from baseline
Time frame: Baseline to Week 2, Week 6, Week 12
Urinary urgency rate
The change in the average number of urinary urgency (Urgency Rating Scale; URS≥2)per day at 2, 6 and 12 weeks from baseline
Time frame: Baseline to Week 2, Week 6, Week 12
Ran from May 2020 to primary completion in Apr 2021, 11 months.
Of 20 industry-sponsored phase 1 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 11 months is above that.
Counting every sponsor, half of 30 studies reached it within 9 months; a quarter within 4 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Hugel